The acquisition of Aliada Therapeutics will grant AbbVie access to a neuroscience-focused technology platform and an ...
AbbVie has agreed to pay $1.4 billion to buy Aliada Therapeutics. The acquisition will give AbbVie control of an Alzheimer’s ...
The purchase of Aliada Therapeutics is “interesting for a number of reasons,” according to a Stifel analyst, one of which is ...
U.S. drugmaker AbbVie said on Monday it will buy Aliada Therapeutics for $1.4 billion in cash, betting on an experimental ...
AbbVie has boosted its Alzheimer's disease pipeline with a $1.4 billion cash deal to buy Aliada Therapeutics and its ...
AbbVie and Aliada Therapeutics have announced a definitive agreement under which AbbVie will acquire Aliada, a biotechnology ...
The acquisition will allow AbbVie to accelerate development of ALIA-1758, a potential disease-modifying therapy for Alzheimer ...
The acquisition of Aliada Therapeutics gives AbbVie access to a Phase I anti-amyloid antibody as well as the biotech’s novel ...
Discover the major biotech partnerships, collaborations, and mergers and acquisitions that made headlines in October 2024.
GlobalData on MSN6d
AbbVie signs agreement to acquire Aliada for $1.4bnAbbVie has entered a definitive agreement to acquire all outstanding equity of Aliada Therapeutics in a $1.4bn cash deal. The ...
AbbVie (ABBV) to acquire Aliada Therapeutics for $1.4B in cash, enhancing focus on Alzheimer's disease with innovative ...
AbbVie (NYSE: ABBV) and Aliada Therapeutics today announced a definitive agreement under which AbbVie will acquire Aliada, a biotechnology company advancing therapies using a novel blood-brain barrier ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback